Notice2025-21301
Foreign-Trade Zone (FTZ) 177; Authorization of Limited Production Activity; AstraZeneca Pharmaceuticals LP; (Pharmaceutical Products); Mount Vernon, Indiana
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
November 26, 2025
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 90 Issue 226 (Wednesday, November 26, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 226 (Wednesday, November 26, 2025)]
[Notices]
[Page 54290]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-21301]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-19-2025]
Foreign-Trade Zone (FTZ) 177; Authorization of Limited Production
Activity; AstraZeneca Pharmaceuticals LP; (Pharmaceutical Products);
Mount Vernon, Indiana
On March 27, 2025, AstraZeneca Pharmaceuticals LP submitted a
notification of proposed production activity to the FTZ Board for its
facility within Subzone 177A, in Mount Vernon, Indiana.
The notification was processed in accordance with the regulations
of the FTZ Board (15 CFR part 400), including notice in the Federal
Register inviting public comment (90 FR 14599, April 3, 2025). On
November 14, 2025, the applicant was notified of the FTZ Board's
decision that the proposed activity has been authorized on a limited
basis, subject to the FTZ Act and the Board's regulations, including
section 400.14, and subject to a three-year limited authorization as
well as a requirement that after two years, AstraZeneca demonstrate to
the satisfaction of the FTZ Board that any foreign status API be
sourced from trusted, secure providers that manufacture in countries
with adequate health and safety regulations that are not in countries
of concern. AstraZeneca may submit requests for the FTZ Board to review
proposed sources of API, and the FTZ Board should ordinarily review
such applications within 90 days of receiving the request.
Dated: November 24, 2025.
Elizabeth Whiteman,
Executive Secretary.
[FR Doc. 2025-21301 Filed 11-25-25; 8:45 am]
BILLING CODE 3510-DS-P
</pre></body>
</html>Indexed from Federal Register on November 26, 2025.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.